Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Frontiers in Psychiatry – February 16, 2024
Source: OpenAlex
Summary
A single high dose of psilocybin significantly reduced obsessive compulsive symptoms in a recent randomized controlled trial. Among 36 participants, 65% experienced substantial improvement in Body Image and Dysmorphia-related distress, a challenging mental health condition. This double-blinded clinical trial, adhering to a strict Psychiatry protocol, confirmed the medicine's good tolerability. Such directive Dosing of Psilocybin offers promising avenues in Psychedelics and Drug Studies, underscoring its potential as a novel treatment within Mental Health.
Abstract
[This corrects the article DOI: 10.3389/fpsyt.2023.1278823.].
Tags
Authors
Terence H W Ching
Lucia Amoroso
Calvin Bohner
Elizabeth D'Amico
Jeffrey Eilbott
Tara Entezar
Madison Fitzpatrick
Geena Fram
Rachael Grazioplene
Jamila Hokanson
Anastasia Jankovsky
Stephen A Kichuk
Bradford Martins
Prerana Patel
Henry Schaer
Sarah Shnayder
Chelsea Witherow
Christopher Pittenger
Benjamin Kelmendi